株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

早産 (子宮収縮抑制) :パイプライン製品の分析

Premature Labor (Tocolysis) - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 245999
出版日 ページ情報 英文 60 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.18円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
早産 (子宮収縮抑制) :パイプライン製品の分析 Premature Labor (Tocolysis) - Pipeline Review, H2 2016
出版日: 2016年08月24日 ページ情報: 英文 60 Pages
概要

早産 (早期分娩) は「妊娠後36週間を経ずに分娩が始まること」と定義されています。主な症状として、骨盤・下腹部への圧迫感や、軽度の膣部痙攣、下痢、膣出血、持続的で重い腰痛などが挙げられます。主な治療薬として、コルチコステロイドや子宮収縮抑制剤などがあります。

当レポートでは、世界各国での早期分娩 (陣痛抑制) 治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要 (製品概要、標的、作用機序、研究開発 (R&D) の進展状況)、最新の業界動向などを調査して、その結果をお届けします。

イントロダクション

  • 分析範囲

早産 (子宮収縮抑制) の概要

治療薬の開発

  • 早産 (子宮収縮抑制) 向けパイプライン製品:概要
  • 早産 (子宮収縮抑制) 向けパイプライン製品:比較分析

各企業で開発中の早産(子宮収縮抑制)治療薬

大学/研究機関で研究中の早産 (子宮収縮抑制) 治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

早産 (子宮収縮抑制) 治療薬:開発中の製品の一覧(企業別)

早産 (子宮収縮抑制) 治療薬:研究中の製品の一覧(大学/研究機関別)

早産 (子宮収縮抑制) 治療薬の開発に従事している企業

  • Actavis plc
  • GlaxoSmithKline plc
  • キッセイ薬品工業
  • Lipocine Inc.
  • ObsEva SA

早産 (子宮収縮抑制):治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • AT-814
    • 製品概要
    • 作用機序 (MoA)
    • 研究開発 (R&D) の進展状況
  • 硫酸ベドラドリン
  • カプロン酸ヒドロキシプロゲステロン
  • OBE-001
  • OBE-002
  • 第二世代プロゲステロン
  • retosiban
  • 早産向けのプロゲステロン受容体刺激用の小分子
  • 早産向け小分子

早産 (子宮収縮抑制) 治療薬:最新の薬剤プロファイル

早産 (子宮収縮抑制) 治療薬:開発が休止状態の製品

早産 (子宮収縮抑制) 治療薬:開発が中止された製品

早産 (子宮収縮抑制) 関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース (全10件)

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8400IDB

Summary

Global Markets Direct's, 'Premature Labor (Tocolysis) - Pipeline Review, H2 2016', provides an overview of the Premature Labor (Tocolysis) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Premature Labor (Tocolysis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Premature Labor (Tocolysis) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Premature Labor (Tocolysis)
  • The report reviews pipeline therapeutics for Premature Labor (Tocolysis) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Premature Labor (Tocolysis) therapeutics and enlists all their major and minor projects
  • The report assesses Premature Labor (Tocolysis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Premature Labor (Tocolysis)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Premature Labor (Tocolysis)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Premature Labor (Tocolysis) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Premature Labor (Tocolysis) Overview
  • Therapeutics Development
    • Pipeline Products for Premature Labor (Tocolysis) - Overview
    • Pipeline Products for Premature Labor (Tocolysis) - Comparative Analysis
  • Premature Labor (Tocolysis) - Therapeutics under Development by Companies
  • Premature Labor (Tocolysis) - Therapeutics under Investigation by Universities/Institutes
  • Premature Labor (Tocolysis) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Premature Labor (Tocolysis) - Products under Development by Companies
  • Premature Labor (Tocolysis) - Products under Investigation by Universities/Institutes
  • Premature Labor (Tocolysis) - Companies Involved in Therapeutics Development
    • AMAG Pharmaceuticals, Inc.
    • GlaxoSmithKline Plc
    • Juniper Pharmaceuticals, Inc.
    • Kissei Pharmaceutical Co., Ltd.
    • Lipocine Inc.
    • ObsEva SA
  • Premature Labor (Tocolysis) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • bedoradrine sulfate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hydroxyprogesterone caproate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hydroxyprogesterone caproate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OBE-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OBE-022 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • progesterone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • retosiban - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Acute Inflammation and Premature Labor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize Progesterone Receptor for Preterm Birth - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Premature Labor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Premature Labor (Tocolysis) - Dormant Projects
  • Premature Labor (Tocolysis) - Discontinued Products
  • Premature Labor (Tocolysis) - Product Development Milestones
    • Featured News & Press Releases
      • Jul 28, 2016: ObsEva Initiates Phase 1 Clinical Program of OBE022, a First-in-Class Orally Active Prostaglandin F2a Antagonist, for the Treatment of Preterm Labor
      • Apr 04, 2016: AMAG Pharmaceuticals Announces the U.S. Commercial Launch of New Single-Dose, Preservative-Free Makena (hydroxyprogesterone caproate injection)
      • Feb 23, 2016: AMAG Pharmaceuticals Announces FDA Approval of New Single-Dose, Preservative-Free Makena (hydroxyprogesterone caproate injection)
      • Feb 16, 2016: Lipocine Reports Positive Results of Multi-Dose Pharmacokinetic Study of LPCN 1107 for the Prevention of Preterm Birth in Pregnant Women
      • Jan 11, 2016: Juniper Pharmaceuticals provides Update on JNP-0301
      • Nov 23, 2015: AMAG Pharmaceuticals Responds to Recent Complete Response Letter From the FDA for the Single-Dose, Preservative-Free Vial of Makena
      • Nov 18, 2015: AMAG Pharmaceuticals Receives Complete Response Letter From FDA for Single-Dose, Preservative-Free Vial of Makena (hydroxyprogesterone caproate injection)
      • Nov 04, 2015: ObsEva Presents Pharmacology Data Showing that OBE002, the First Orally Active Prostaglandin F2a Antagonist, is devoid of the side effects associated with NSAID treatment of Preterm Labor
      • Sep 01, 2015: ObsEva Presents Pharmacology Data Showing that OBE001, the First Orally Active Oxytocin Antagonist, Inhibits not only Uterine Contractions but also Preterm Labor Related Inflammation Pathways
      • Jun 23, 2015: ObsEva Announces Recruitment of the First Patient in TERM Phase 2 Study - Clinical Trial to Evaluate the Safety and Efficacy of OBE001 for Delaying Spontaneous Preterm Labor in Pregnant Women
      • May 28, 2015: AMAG Pharmaceuticals Receives Complete Response Letter From FDA for the Single-Dose Vial of Makena
      • May 20, 2015: AMAG Pharmaceuticals Expands Resources Dedicated to Reducing the Risk of Preterm Birth
      • Mar 17, 2015: GSK announces start of phase III programme to evaluate retosiban for spontaneous preterm labour
      • Feb 26, 2015: ObsEva Reports Positive Phase 1 Results for the First Orally Active Oxytocin Antagonist OBE001 to Treat Preterm Labour
      • Jul 02, 2012: FDA Issues Further Guidance On K-V Pharma's Makena
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Premature Labor (Tocolysis), H2 2016
  • Number of Products under Development for Premature Labor (Tocolysis) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Premature Labor (Tocolysis) - Pipeline by AMAG Pharmaceuticals, Inc., H2 2016
  • Premature Labor (Tocolysis) - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Premature Labor (Tocolysis) - Pipeline by Juniper Pharmaceuticals, Inc., H2 2016
  • Premature Labor (Tocolysis) - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2016
  • Premature Labor (Tocolysis) - Pipeline by Lipocine Inc., H2 2016
  • Premature Labor (Tocolysis) - Pipeline by ObsEva SA, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Premature Labor (Tocolysis) - Dormant Projects, H2 2016
  • Premature Labor (Tocolysis) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Premature Labor (Tocolysis), H2 2016
  • Number of Products under Development for Premature Labor (Tocolysis) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
Back to Top